BioSpace News Archive

The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Omaveloxolone (Skyclarys), the first ever treatment for Friedreich’s Ataxia (FA), a rare neuromuscular disease on Rare Disease Day today, February 28.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

Modern Meadow announced its Bio-Alloy™ proprietary protein-based technology is coming to the Tory Burch runway as the American fashion brand debuts its first-ever plant-based leather alternative tote, the Ella Bio, an evolution of the iconic Ella tote.

Today, UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced it has been granted a patent for real-time guidance of ultrasound devices.

Xylyx Bio, a New York-based regenerative medicine company leading the development of advanced biomaterials and biosystems, is proud to announce the launch of their redesigned website showcasing the company’s growing portfolio of regenerative biotechnologies.

Endonovo Therapeutics, Inc. (OTCQB: ENDV), a medical device company specializing in pulsed electromagnetic field (PEMF) technology, announced today it will hold a question and answer session for shareholders on March 9, 2023 at 4:30pm EST with Ira Weisberg, President of Endonovo’s Medical Division.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new cancer profiling solution.

Ymmunobio announced today that it has been granted Orphan Drug Designation (ODD) by the US Food & Drug Administration (FDA) for YB-200, a CEACAM1/5 antibody it is studying for the treatment of hepatocellular carcinoma (HCC).

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development.

Moss Genomics Inc. (CSE: MOSS) (“Moss” or the “Company”), a consumer genomics and gut microbiome company based in Vancouver, British Columbia, announces that the Company has granted incentive stock options to certain directors, officers and consultants to acquire 1,320,000 common shares of the Company at a price of C$0.10 per share, vesting immediately.